MediXall (MDXL) Debt to Equity (2020 - 2024)
MediXall's Debt to Equity history spans 4 years, with the latest figure at -$0.06 for Q3 2024.
- For Q3 2024, Debt to Equity rose 91.37% year-over-year to -$0.06; the TTM value through Sep 2024 reached -$0.06, up 91.37%, while the annual FY2023 figure was -$0.59, 15.12% up from the prior year.
- Debt to Equity reached -$0.06 in Q3 2024 per MDXL's latest filing, up from -$0.59 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.37 in Q4 2020 to a low of -$0.76 in Q2 2022.
- Average Debt to Equity over 4 years is -$0.53, with a median of -$0.65 recorded in 2022.
- Peak YoY movement for Debt to Equity: decreased 6.65% in 2023, then soared 91.37% in 2024.
- A 4-year view of Debt to Equity shows it stood at $0.37 in 2020, then plummeted by 289.53% to -$0.7 in 2022, then rose by 15.12% to -$0.59 in 2023, then surged by 89.85% to -$0.06 in 2024.
- Per Business Quant, the three most recent readings for MDXL's Debt to Equity are -$0.06 (Q3 2024), -$0.59 (Q2 2024), and -$0.6 (Q1 2024).